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Introduction: No consensus exists on optimum therapy for older cancer patients. This singlecentre study
was conducted to review the treatment and outcomes for octogenarian women treated for breast cancer.
Methods: Data of all elderly breast cancer patients (80 years) with primary breast cancer treated at out
institution between 1990 and 2009. Patients with carcinoma in-situ (stage 0) and advanced breast cancer
(stage IV) were excluded. Breast cancer-speciﬁc survival and disease-free survival for the different pa-
tient groups were analysed according to the KaplaneMeier method.
Results: The study population consisted of 259 patients (median age 84 years). There were 189 (73%)
patients with early stage disease (I, IIA, IIB) and 70 (27%) with locally advanced disease (IIIA, IIIB, IIIC). A
total of 175 (67.7%) patients underwent surgical treatment and 84 (32.4%) received primary endocrine
treatment. Patients were followed for a median of 65 months. In patients with early stages, the mean
breast cancer-speciﬁc survival was 108 months (95% CI 101e115) in the surgical group and 50 months
(95% CI 39e61) in the non-surgical group (P < 0.01), whereas patients with locally advanced breast
cancer breast cancer-speciﬁc survival was similar for the surgical and non-surgical groups. Breast cancer-
speciﬁc survival and disease-free survival were signiﬁcantly better among patients who underwent
standard surgical treatment than among those with suboptimal surgery.
Conclusion: In women 80 years with early-stage breast cancer, standard surgical treatment as compared
with non-surgical therapy was associated with a better breast cancer-speciﬁc.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Increasing life expectancy in the United States and European
populations has been associated with an increase in the incidence
of breast cancer in elderly women. Ageing remains one of the single
greatest risk factors for the development of new breast cancer, and
more than 30% of breast cancers occur after age of 75.1,2 Breast
cancer management in elderly women remains a complex problem
for clinicians and there is disagreement about the optimum treat-
ment. In spite of apparently favourable prognostic factors, such as
low grade tumour types, smaller incidence of axillary lymph nodeþ34 93 2746715.
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ciates Ltd. Published by Elsevier Ltinvolvement and vascular invasion, estrogen receptor-positive
disease, and less aggressive tumour biology,3e6 elderly breast
cancer patients often receive less than the standard of care when
compared with their younger counterparts.7,8 Primary endocrine
therapy is sometimes substituted for operation, and axillary sur-
gery, adjuvant chemotherapy and adjuvant radiotherapy are
frequently omitted.9 A Cochrane review of surgery versus primary
endocrine therapy for operable primary breast cancer in women 70
years or over showed that surgery controls breast cancer better
than tamoxifen alone with signiﬁcant differences in progression-
free survival, but does not extend overall survival.10 Moreover,
much of the literature deﬁnes “elderly” very broadly, including
women as young as 65 or even excluding women over 80 from
studies focused on older breast cancer patients. There is a paucity of
data for the “oldest old” patients and to date differences in outcome
between surgery and primary endocrine treatment in breast cancer
octogenarians has been poorly assessed.9,11e13
This study was conducted to reviewmanagement and outcomes
for women 80 years and older treated for breast cancer at ourd. All rights reserved.
Table 1
Distribution of breast cancer stages in the surgical and non-surgical groups.
Stage Total patients Primary surgical
treatment (n ¼ 175)
Primary endocrine
therapy (n ¼ 84)
Early stages
I 40 33 (82.5) 7 (17.5)
IIA 90 74 (82.2) 16 (17.8)
IIB 59 43 (72.9) 16 (27.1)
Locally advanced
IIIA 12 9 (75) 3 (25)
IIIB 56 15 (26.8) 41 (73.2)
IIIC 2 1 (50) 1 (50)
Percentages in parenthesis.
Fig. 1. Differences in breast cancer-speciﬁc survival between the surgical and non-
surgical treatment groups.
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survival between surgically and non-surgically treated patients as
well as between patients undergoing standard versus suboptimal
surgical treatment.
2. Patients and methods
We conducted a retrospective study of all elderly breast cancer patients (80
years) with primary breast cancer treated at out institution between 1995 and 2009.
Patients with carcinoma in-situ (stage 0) and advanced breast cancer (stage IV) were
excluded. Data were collected from the medical records. Follow-up information
(vital status) was obtained from medical charts or by telephone contact with the
patients, their family or their family physician. Causes of death were also deter-
mined from medical records by telephone or from main data resources when
available. Institutional review board approval was obtained prior to the
commencement of this retrospective study. Written informed consent of the pa-
tients was not required.
Data collected included demographic details, histological type, age at the initial
diagnosis, clinical stage, receptor status, presence of lymphovascular invasion,
treatment modalities including surgical resection, adjuvant chemotherapy, endo-
crine therapy and radiotherapy. The ﬁrst sentinel lymph node biopsy performed in
this series of patients occurred in 2001.
Patients were divided into two groups, those who received primary surgical
treatment and those who received primary endocrine therapy. Patients in both
groups were stratiﬁed into early (I, IIA, IIB) and locally advanced (III) stages. In our
unit, all patients of all ages diagnosed with breast cancer stages I, II, and III are
candidates to surgical treatment except if there are anaesthetic contraindications.
Patients >80 years of age were informed on the non-surgical alternative of endo-
crine therapy with good results. Therefore, the decision to be treated conservatively
mainly depended on the decision of the patients or relatives, and to a lower extent
by a formal contraindication on the part of the anaesthetist. Surgically-treated pa-
tients were also classiﬁed into those undergoing standard surgical treatment ful-
ﬁlling oncological criteria, including mastectomy, simple mastectomy and sentinel
lymph node biopsy, margin-free lumpectomy and sentinel lymph node biopsy or
margin-free lumpectomy and axillary dissection, and those undergoing suboptimal
surgical treatment, including mastectomy or margin-free lumpectomy without
assessment of axillary lymph node involvement, resection of palpable lymph nodes
only or axillary sampling.
2.1. Statistical analysis
Differences in demographic and clinical variables between the surgical and non-
surgical groups were assessed with the chi-square (c2) test for categorical variables
and the Student’s t test or the ManneWhitney U test for quantitative variables.
Statistical signiﬁcance was set at P < 0.05. Breast cancer-speciﬁc survival and
disease-free survival for the different patient groups were analysed according to the
KaplaneMeier method by using SPSS software (version 17.0; SPSS Inc., Chicago, IL).
Differences in survival were assessed with log-rank test.
3. Results
A total of 360 patients aged 80 years presented with primary
breast cancer between 1995 and 2009. Of these, 45 patients had
carcinoma in situ (stage 0, n ¼ 20) or advanced disease (stage IV,
n ¼ 25) and were excluded from the study. Fifty-six patients in
whom information regarding vital status at the time of analysis
could not be obtained were also excluded.
The study population consisted of 259 patients. Median age at
diagnosis was 84 years (range, 80e99 years). There were 189 (73%)
patients with early stages of disease and 70 (27%) with locally
advanced disease. A total of 175 (67.7%) patients underwent sur-
gical treatment, and the other 84 (32.4%) received primary endo-
crine treatment. The distribution of patients in the surgical and
non-surgical groups in relation to clinical stages is shown in
Table 1. Patients in the surgical group were younger (mean age 83.8
years, 95% conﬁdence interval [CI] 83.3e84.3) than those in the
non-surgical group (mean age 85.2 years, 95% CI 84.5e85.9) but
differences were not statistically signiﬁcant. When the surgical and
non-surgical groups were compared, signiﬁcant differences in the
percentage of patients with positive estrogen receptors (78.8% vs
86.9%), presence of lymphovascular invasion (86.8% vs 88.1%), and
use of chemotherapy (17.1% vs 11.9%) and radiotherapy (24% vs 19%)were not found. Eighty percent of patients in the surgical groups
received hormonal treatment (tamoxifen, aromatase inhibitors) as
compared with 75% in the non-surgical group.
Patients were followed for a median of 65 months. A total of 80
patients died of breast cancer (31%) and the remaining 179 patients
(69%) of other causes. In the group of 189 patients with early stages
of breast cancer, there were 150 (79.4%) patients in the surgical
group and the remaining 39 in the non-surgical group. As shown in
Fig. 1, the mean breast cancer-speciﬁc survival was 108 months
(95% CI 101e115) in the surgical group of patients with early-stage
disease as compared with 50 months (95% CI 39e61) in the non-
surgical group (P < 0.01). However, in patients with locally
advanced breast cancer (n ¼ 70), the mean breast cancer-speciﬁc
survival was similar for patients in the surgical (n ¼ 25) and non-
surgical (n ¼ 45) groups (76 months, 95% CI 62e89 vs 68 months
(95% CI 49e86) (P ¼ 0.071).
Of the 175 patients treated surgically, 150 (85.7%) received
standard or optimal surgical treatment. In the remaining 25 pa-
tients, surgical operation was considered suboptimal. As shown in
Fig. 2, breast cancer-speciﬁc survival was signiﬁcantly better among
patients who underwent standard surgical treatment (108 months,
95% CI 101e115) than among those with suboptimal surgical
treatment (71 months, 95% CI 71e108) (P ¼ 0.008). Differences in
disease-free survival were also observed (110 months, 95% CI 102e
118 for standard surgery vs 77 months, 95% CI 60e95 for subopti-
mal surgery) (P ¼ 0.04) (Fig. 3).
4. Discussion
Breast cancer management in elderly women remains a com-
plex problem for clinicians and there is disagreement about the
optimum treatment. Moreover, it is often assumed that therapy
Fig. 2. Breast cancer-speciﬁc survival was signiﬁcantly longer among patients who
underwent standard surgical treatment than among patients with suboptimal surgical
treatment.
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cancer patients. Part of this controversy results from some common
misconceptions, such as the elderly have a limited life expectancy
because of comorbid conditions, or that breast cancer mortality
among the elderly is a marginal problem because of the increased
risk of death from other causes. In a series of 134 women80 years
old reported by Cyr et al.,12 only 4% died of breast cancer. In a
retrospective series of 100 patients more than 70 years old with
breast cancer who underwent radical surgery between 1990 and
1998, de la Haba Rodríguez et al.14 progression of breast cancer was
the main cause of death. In the study of Evron et al.13 of 135 women
with localized breast cancer at age 80 years or older, breast cancer
was the cause of death in 35.3% of the patients, which is consistent
with 31% of deaths due to breast cancer found in our study.
Bouchardy et al.11 in a review of the clinical ﬁles of 407 breast
cancer patients aged 80 years, 5-year speciﬁc breast cancer sur-
vival was 51% for tamoxifen alone as compared with 82% for mas-
tectomy and 90% for breast-conservative surgery plus adjuvant
treatment. The authors conclude that undertreatment of elderly
patients with breast cancer strongly decreases speciﬁc survival,
which is in agreement with results of the present study. In the
GRETA trial,15 surgery (radical or minimal) followed by adjuvant
tamoxifen does not modify overall and breast cancer survival asFig. 3. Differences in disease-free survival for standard surgical treatment and sub-
optimal surgery.compared with tamoxifen alone; however, in those patients who
received the primary endocrine treatment, there was a high rate of
local progression. Also, better survival in the surgical treatment
group when compared with the primary endocrine treatment
group was documented in the study of Rao et al.9 In our study,
breast cancer-speciﬁc survival was signiﬁcantly better in the sur-
gical group but only in patients with early-stage breast cancer,
whereas differences in the modality of treatment in patients with
locally advanced breast cancer were not found.
The role of radiotherapy in older women with breast cancer is
controversial because of eventual serious adverse effects. In our
study, 22.4% received radiation therapy but different studies have
shown the underuse of radiation therapy in older breast cancer
patients.16,17 In a study of 636 women who were 70 years of age or
older with clinical stage I and estrogen-receptor-positive breast
carcinoma treated by lumpectomy, tamoxifen plus radiation ther-
apy versus tamoxifen alone showed similar results with regard to
the rates of mastectomy for local recurrence, distant metastases, or
ﬁve-year rates of overall survival. The only signiﬁcant difference
between the two groups was in the rate of local or regional recur-
rence at 5 years (1% in the group given tamoxifen plus irradiation
and 4% in the group given tamoxifen alone, P< 0.001).18 In contrast,
in a cohort of 1837 women having operations for stage I or II breast
cancer aged 65 years or older, patients receiving breast-
conservative surgery without radiation therapy were twice as
likely to die of breast cancer compared with women receiving
mastectomy.19 Breast cancer mortality rates were similar between
women receiving breast-conservative surgery plus radiotherapy
and women receiving mastectomy.19
We found that standard surgical treatment in octogenarian
breast cancer patients as compared with suboptimal surgical
treatment was associated with a better breast cancer-speciﬁc sur-
vival and disease-free survival. However, in the study of Evron
et al.13 standard local treatment that comprised modiﬁed radical
mastectomy or margin-free lumpectomy and axillary dissection
followed by radiation showed no signiﬁcant differences in overall
survival and breast cancer-speciﬁc survival as compared with less
than standard local treatment where either radiotherapy or axillary
dissection or both were withheld.
Limitations of the study include the retrospective nature and the
fact that data on comorbidities were not consistently registered.
However, this study has highlighted signiﬁcant breast cancer-
speciﬁc survival in the surgical treatment group as compared
with primary endocrine therapy for elderly patients with early-
stage breast cancer. In agreement with other studies20 there is no
reason why age should be a consideration in the management of
breast cancer. Breast cancer octogenarians should receive optimal
oncological surgical treatment as younger patients. Primary endo-
crine therapy may be provided to patients who refuse or are unﬁt
for surgery. Involvement of a multidisciplinary team including
multidimensional geriatric evaluation permits a better selection
and individualized therapeutic decision for each patient.
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